|
시장보고서
상품코드
2032493
울혈성 심부전 치료제 시장 : 약제 클래스별, 투여 경로, 유통 채널, 지역별(2026-2034년)Congestive Heart Failure Drugs Market by Drug Class, Route of Administration, Distribution Channel, and Region 2026-2034 |
||||||
세계의 울혈성 심부전 치료제 시장 규모는 2025년에 104억 달러에 이르렀습니다. 향후 IMARC Group은 2034년까지 시장 규모가 256억 달러에 이르고, 2026-2034년 CAGR 10.19%를 나타낼 것으로 예측했습니다. 비만 및 심혈관 질환의 유병률 증가, 고령 인구 증가, 건강에 해로운 식습관 등이 시장을 주도하는 주요 요인으로 작용하고 있습니다.
울혈성 심부전은 심근의 펌프 기능에 영향을 미치는 질환입니다. 일반적으로 고혈압, 관상동맥질환, 당뇨병, 비만, 과도한 알코올 섭취로 인해 발생합니다. 그 증상으로는 누웠을 때 숨가쁨, 쇠약감, 피로감, 복부-다리-발목 부종, 야간 빈뇨, 메스꺼움, 집중력 저하 등이 있습니다. 건강한 체중 유지, 신체 활동의 지속, 혈압 및 혈당 관리로 예방이 가능합니다. 이 외에도 혈전 예방, 혈관 확장, 심장 수축 강화, 심장 기능 개선에 도움이 되는 다양한 처방약을 사용하여 관리합니다. 현재 ACE 억제제, 혈관 확장제, 디기탈리스 배당체, 이뇨제, 베타 차단제 등이 울혈성 심부전에 가장 많이 처방되는 약물입니다. 이 중 ACE 억제제는 혈관을 수축시키는 안지오텐신 생성을 억제하고, 베타차단제는 특정 화학물질의 작용을 억제합니다.
현재 당뇨병과 만성 심혈관 질환에 취약한 고령 인구가 전 세계적으로 증가하고 있는 것이 시장에 긍정적인 영향을 미치는 주요 요인 중 하나입니다. 또한, 과도한 흡연과 음주, 건강에 해로운 식습관이 결합되어 심장 질환의 위험이 증가하고 있으며, 이는 전 세계적으로 울혈성 심부전 치료제에 대한 수요를 증가시키고 있습니다. 여기에 비만과 운동 부족으로 인한 심장병 발병률 증가는 현재 시장 성장을 견인하고 있습니다. 또한, 심장 질환의 조기 진단 및 치료의 이점에 대한 개인들의 인식이 높아지면서 시장 전망이 밝아지고 있습니다. 이와는 별도로, 효과적인 약물 및 치료법에 대한 수요 증가와 규제 당국의 승인은 주요 시장 기업에게 유망한 성장 기회를 제공합니다. 또한, 의료 인프라 개선과 환자들에게 최적의 치료를 제공하기 위한 각국 정부의 이니셔티브도 시장 성장에 기여하고 있습니다. 또한, 병원과 주택가의 약국 확대, 저렴한 가격으로 의약품을 쉽게 구할 수 있고, 안전한 온라인 결제 수단을 제공하는 급성장하는 전자상거래 산업도 시장 성장을 가속할 것으로 예측됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 울혈성 심부전 치료제 시장
제6장 시장 분석 : 약제 클래스별
제7장 시장 분석 : 투여 경로별
제8장 시장 분석 : 유통 채널별
제9장 시장 분석 : 지역별
제10장 촉진, 억제 및 기회
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
JHS 26.05.18The global congestive heart failure drugs market size reached USD 10.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.6 Billion by 2034, exhibiting a growth rate (CAGR) of 10.19% during 2026-2034. The rising prevalence of obesity and cardiovascular problems, increasing geriatric population and unhealthy dietary habits represent some of the key factors driving the market.
Congestive heart failure is a medical condition that affects the pumping ability of the heart muscle. It is generally caused by hypertension, coronary artery disease, diabetes, obesity, and excessive alcohol consumption. Its symptoms include shortness of breath while lying down, weakness, fatigue, swelling in the abdomen, feet, and ankles, frequent urination at night, nausea, and difficulty in concentration. It can be prevented by maintaining a healthy weight, staying physically active, and controlling blood pressure and glycemic levels. Besides this, it is controlled using various prescribed drugs that help prevent blood clots, expand blood vessels, strengthen the contractions of the heart, and improve heart functioning. At present, ACE inhibitors, vasodilators, digitalis glycosides , diuretics, and beta-blockers are some of the most prescribed congestive heart failure drugs. Amongst these, ACE inhibitors prevent the formation of angiotensin, which causes blood vessels to constrict, and beta blockers block the actions of certain chemicals.
Presently, the increasing global geriatric population, which is highly susceptible to diabetes and chronic cardiovascular diseases, represents one of the major factors positively influencing the market. In addition, excessive smoking and drinking of alcoholic beverages, coupled with unhealthy dietary habits of individuals, increases the risks of heart problems, which is catalyzing the demand for congestive heart failure drugs across the globe. This, coupled with the rising occurrence of heart problems due to obesity and lack of physical activity, is currently strengthening the growth of the market. Furthermore, the increasing awareness among individuals about the benefits of early diagnosis and treatment of heart disease is creating a positive outlook for the market. Apart from this, the escalating demand for effective drugs and treatment and their approval from authorized agencies offer lucrative growth opportunities to the leading market players. Moreover, initiatives undertaken by governments of various countries to improve healthcare infrastructure and provide optimal care to patients are contributing to the growth of the market. Additionally, the expansion of pharmacies in hospitals and residential areas and the burgeoning e-commerce industry providing easy availability of medicines at affordable rates and the facility of secured online payment methods are expected to propel the growth of the market.
KEY MARKET SEGMENTATION:
Drug Class Insights:
- ACE Inhibitors
- Angiotensin 2 Receptor Blockers
- Beta Blockers
- Diuretics
- Aldosterone Antagonists
- Inotropes
- Others
The report has also provided a detailed breakup and analysis of the congestive heart failure drugs market based on the drug class. This includes ACE inhibitors, angiotensin 2 receptor blockers, beta blockers, diuretics, aldosterone antagonists, inotropes, and others. According to the report, ACE inhibitors represented the largest segment.
Route of Administration Insights:
- Oral
- Intravenous
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (The United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. According to the report, North America was the largest market for congestive heart failure drugs. Some of the factors driving the North America market included the development of healthcare infrastructure, increasing cases of heart failure and the easy availability of technologically advanced devices and innovative drugs.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global congestive heart failure drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG), Novartis AG, etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Congestive Heart Failure Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Class
- 6.1 ACE Inhibitors
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Angiotensin 2 Receptor Blockers
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Beta Blockers
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Diuretics
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Aldosterone Antagonists
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Inotropes
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intravenous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AstraZeneca plc
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Bayer AG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG)
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Novartis AG
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.1 AstraZeneca plc
